For instance, clinical trials of sirolimus, an mTOR inhibitor efficacious in preclinical trials, showed no clinical benefit, mostly due to its toxicity prevented adequate dosing to delay the disease progression in human ADPKD [22]. Here, MTOR is linked to autosomal dominant polycystic kidney disease.